Patients with type 2 diabetes mellitus (T2DM) prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have ...

Researchers have identified that glucagon-like peptide-1 receptor agonists (GLP-1 RAs), which are widely used to control type ...

Preliminary study shows GLP-1 receptor agonists alter alcohol response, suggesting potential for reducing cravings and ...

A Medicare cohort study of nearly 4 million older patients with type 2 diabetes found 2 in 1000 developed nonarteritic anterior ischemic optic neuropathy (NAION) over a period of more than 3 years.

Use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs), particularly semaglutide and tirzepatide, was associated with a 37% reduced risk for dementia and a 19% reduced risk for ischemic stroke ...

The use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) before surgery rose 16-fold among patients undergoing metabolic and bariatric surgery from 2020 to 2024.

"Although there was a signal of lower incidence of dementia with GLP-1 RAs than with DPP4is among adults younger than 75 years, the causal relationship remains unclear." HealthDay News — For older ...

Association seen in seniors with type 2 diabetes; greater associations seen for semaglutide and liraglutide. (HealthDay News) — For older adults with type 2 diabetes, glucagon-like peptide-1 receptor ...

Overweight patients waiting for operations could safely use a particular type of weight-loss treatment to reduce the risk of surgical complications linked to their obesity, a new study reveals. The ...

About The Study: In this cohort study of patients with type 2 diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) use was associated with body mass index (BMI) -dependent cardiovascular ...

An increased risk for nonarteritic anterior ischemic optic neuropathy was seen in association with 2 GLP-1 RAs (hazard ratios, 1.39 and 1.25 for semaglutide and liraglutide, respectively). HealthDay ...